API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
40
PharmaCompass offers a list of Docusate Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Docusate Sodium manufacturer or Docusate Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Docusate Sodium manufacturer or Docusate Sodium supplier.
PharmaCompass also assists you with knowing the Docusate Sodium API Price utilized in the formulation of products. Docusate Sodium API Price is not always fixed or binding as the Docusate Sodium Price is obtained through a variety of data sources. The Docusate Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Manoxol OT manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Manoxol OT, including repackagers and relabelers. The FDA regulates Manoxol OT manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Manoxol OT API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Manoxol OT manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Manoxol OT supplier is an individual or a company that provides Manoxol OT active pharmaceutical ingredient (API) or Manoxol OT finished formulations upon request. The Manoxol OT suppliers may include Manoxol OT API manufacturers, exporters, distributors and traders.
click here to find a list of Manoxol OT suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Manoxol OT DMF (Drug Master File) is a document detailing the whole manufacturing process of Manoxol OT active pharmaceutical ingredient (API) in detail. Different forms of Manoxol OT DMFs exist exist since differing nations have different regulations, such as Manoxol OT USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Manoxol OT DMF submitted to regulatory agencies in the US is known as a USDMF. Manoxol OT USDMF includes data on Manoxol OT's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Manoxol OT USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Manoxol OT suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Manoxol OT Drug Master File in Japan (Manoxol OT JDMF) empowers Manoxol OT API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Manoxol OT JDMF during the approval evaluation for pharmaceutical products. At the time of Manoxol OT JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Manoxol OT suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Manoxol OT Drug Master File in Korea (Manoxol OT KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Manoxol OT. The MFDS reviews the Manoxol OT KDMF as part of the drug registration process and uses the information provided in the Manoxol OT KDMF to evaluate the safety and efficacy of the drug.
After submitting a Manoxol OT KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Manoxol OT API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Manoxol OT suppliers with KDMF on PharmaCompass.
A Manoxol OT CEP of the European Pharmacopoeia monograph is often referred to as a Manoxol OT Certificate of Suitability (COS). The purpose of a Manoxol OT CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Manoxol OT EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Manoxol OT to their clients by showing that a Manoxol OT CEP has been issued for it. The manufacturer submits a Manoxol OT CEP (COS) as part of the market authorization procedure, and it takes on the role of a Manoxol OT CEP holder for the record. Additionally, the data presented in the Manoxol OT CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Manoxol OT DMF.
A Manoxol OT CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Manoxol OT CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Manoxol OT suppliers with CEP (COS) on PharmaCompass.
A Manoxol OT written confirmation (Manoxol OT WC) is an official document issued by a regulatory agency to a Manoxol OT manufacturer, verifying that the manufacturing facility of a Manoxol OT active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Manoxol OT APIs or Manoxol OT finished pharmaceutical products to another nation, regulatory agencies frequently require a Manoxol OT WC (written confirmation) as part of the regulatory process.
click here to find a list of Manoxol OT suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Manoxol OT as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Manoxol OT API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Manoxol OT as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Manoxol OT and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Manoxol OT NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Manoxol OT suppliers with NDC on PharmaCompass.
Manoxol OT Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Manoxol OT GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Manoxol OT GMP manufacturer or Manoxol OT GMP API supplier for your needs.
A Manoxol OT CoA (Certificate of Analysis) is a formal document that attests to Manoxol OT's compliance with Manoxol OT specifications and serves as a tool for batch-level quality control.
Manoxol OT CoA mostly includes findings from lab analyses of a specific batch. For each Manoxol OT CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Manoxol OT may be tested according to a variety of international standards, such as European Pharmacopoeia (Manoxol OT EP), Manoxol OT JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Manoxol OT USP).